Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Macrophage function during the development of adjuvant disease.

E J Schenkelaars1, I L Bonta, S Ferrone

  • 1Erasmus University, Rotterdam, The Netherlands.

Agents and Actions
|January 1, 1990
PubMed
Summary

Adjuvant disease (AD) in rats involves decreased immune cell antigens, increased interleukin-1 (IL-1), and prostaglandin E2 (PGE2). Non-steroidal anti-inflammatory drugs (NSAIDs) partially reversed these effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antagonism of gamma-hydroxybutyrate-induced hypersynchronization in the ECoG of the rat by anti-petit mal drugs.

Neuroscience letters·2009
Same author

A pilot study using a staph protein A column (Prosorba) to treat refractory rheumatoid arthritis.

The Journal of rheumatology·1999
Same author

Modulation of idiotypic and antiidiotypic immunoglobulin G responses in an alloimmune thrombocytopenic patient associated with extracorporeal protein A immunoadsorption.

Artificial organs·1996
Same author

Association of anti-platelet IgG antibody levels with response to extracorporeal protein A/silica immunoadsorption in ITP patients.

American journal of hematology·1995
Same author

Levels of soluble intercellular adhesion molecule 1, eicosanoids and cytokines in ascites of patients with liver cirrhosis, peritoneal cancer and spontaneous bacterial peritonitis.

International journal of immunopharmacology·1995
Same author

Mediators of Inflammation well on track to connect Molecular Pharmacology and Therapeutics.

Mediators of inflammation·1995

Area of Science:

  • Immunology
  • Cell Biology
  • Pharmacology

Background:

  • Adjuvant disease (AD) is an inflammatory condition.
  • Understanding the molecular changes during AD is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the relationship between adjuvant disease development and the expression of class I and II antigens, interleukin-1 (IL-1), and prostaglandin E2 (PGE2).
  • To evaluate the effects of non-steroidal anti-inflammatory drug (NSAID) treatment on these parameters during AD.

Main Methods:

  • Rat peritoneal macrophages and blood monocytes were used to study AD.
  • Measurements included class I and II antigen expression, IL-1 release, and PGE2 production.
  • In vivo treatment with Na-diclofenac and in vitro exposure to lipopolysaccharide were employed.

Related Experiment Videos

Main Results:

  • Class I and II antigens initially decreased, with class II remaining low and class I returning to normal.
  • Prostaglandin E2 (PGE2) and interleukin-1 (IL-1) levels gradually increased during AD.
  • NSAID treatment reduced PGE2 and IL-1 release and partially restored antigen expression.
  • Lipopolysaccharide exposure enhanced class I antigen expression in vitro.

Conclusions:

  • AD is associated with significant alterations in immune cell antigen expression and inflammatory mediator production.
  • NSAID treatment demonstrates potential in mitigating some of the immunological disturbances observed in AD.
  • Further research into the immunomodulatory effects of NSAIDs in AD is warranted.